Director at Dyne Therapeutics (DYN) awarded 57,463 stock options vesting over 3 years
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Dyne Therapeutics, Inc. director Barry E. Greene received a grant of stock options covering 57,463 shares of common stock on June 22, 2026. The options have an exercise price of $20.87 per share and expire on June 21, 2036. The underlying shares are scheduled to vest in equal monthly installments over three years through June 22, 2029, indicating a multi-year equity compensation award rather than an open-market purchase or sale.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Greene Barry E
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock option (right to buy) | 57,463 | $0.00 | -- |
Holdings After Transaction:
Stock option (right to buy) — 57,463 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Options granted: 57,463 options
Exercise price: $20.87 per share
Underlying shares: 57,463 shares
+3 more
6 metrics
Options granted
57,463 options
Stock option grant to director Barry E. Greene on June 22, 2026
Exercise price
$20.87 per share
Exercise price for granted Dyne Therapeutics stock options
Underlying shares
57,463 shares
Common stock underlying the option grant
Total derivative holdings after grant
57,463 options
Total stock options held following this transaction
Vesting period
3 years monthly
Options vest in equal monthly installments through June 22, 2029
Expiration date
June 21, 2036
Expiration of Dyne Therapeutics option grant to Barry E. Greene
Key Terms
Stock option (right to buy), exercise price, vesting, Common Stock, +1 more
5 terms
Stock option (right to buy) financial
"security_title: Stock option (right to buy)"
exercise price financial
"conversion_or_exercise_price: 20.8700"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"shares underlying the option are scheduled to vest over three years in equal monthly installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
Common Stock financial
"underlying_security_title: Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
expiration date financial
"expiration_date: 2036-06-21T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
What did Dyne Therapeutics (DYN) report in this Form 4 for Barry E. Greene?
Dyne Therapeutics reported that director Barry E. Greene received a grant of stock options for 57,463 shares. These options are a compensation award, not an open-market trade, and give him the right to buy common stock at a fixed exercise price.
How many Dyne Therapeutics (DYN) stock options were granted to Barry E. Greene?
Barry E. Greene was granted stock options covering 57,463 shares of Dyne Therapeutics common stock. This entire amount is reflected as his total derivative holdings following the grant, showing a new equity-based compensation position established on the grant date.
What is the exercise price of Barry E. Greene’s Dyne Therapeutics (DYN) stock options?
The granted stock options have an exercise price of $20.87 per share. This means Greene can purchase Dyne Therapeutics common stock at $20.87 per share upon vesting and exercise, regardless of the market price at that time.
When do Barry E. Greene’s Dyne Therapeutics (DYN) stock options vest?
The options vest in equal monthly installments over three years through June 22, 2029. This monthly vesting schedule gradually makes portions of the 57,463 underlying shares exercisable, aligning the award with ongoing board service over that period.
What is the expiration date of Barry E. Greene’s Dyne Therapeutics (DYN) option grant?
The stock options granted to Barry E. Greene expire on June 21, 2036. After this expiration date, any unexercised options will lapse, so the economic value depends on Dyne Therapeutics’ share price before that deadline.
Does this Dyne Therapeutics (DYN) Form 4 show any open-market buying or selling by Barry E. Greene?
No, the filing shows a grant of stock options as compensation, coded as an acquisition (A). There are no open-market purchase or sale transactions reported, only the establishment of a new option position for future potential exercises.